Slide 1: ASX Market Announcement: Corporate & Strategic Update at JP Morgan Biotech Showcase
ASX Market Announcement Genetic Technologies to provide Corporate & Strategic Update at 2020 JP Morgan Biotech Showcase For personal use only Melbourne, AUS – Genetic Technologies (ASX: GTG; NASDAQ: GENE), a leader in the development of genetic risk assessment tests recently announced the commercial
Slide 2: About Genetic Technologies Limited
About Genetic Technologies Limited For personal use only Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products G
Slide 3: Biotech Showcase, 14 January 2020, San Francisco
For personal use only NASDAQ: GENE Biotech Showcase 14 January 2020 San Francisco
Slide 4: Forward looking statements
Forward looking statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 5: Who we are
Who we are For personal use only Genetic Technologies is a leader in genomics • Over a decade of R&D surrounding the development of polygenic risk scores • Developing risk prediction platforms for major oncological, metabolic and degenerative diseases • Strong scientific leadership under Dr Richard
Slide 6: The human genome
The human genome For personal use only In 2003, humanity completed perhaps its most ambitious voyage of exploration when scientists mapped the human genome – the three-billion-plus pairs of DNA that make us human. Advances in genomic epidemiology and sequencing technology will influence the way phys
Slide 7: Polygenic Risk Score
Polygenic Risk Score For personal use only What is it? • Most common complex diseases are a result of not one or a few genes, but many acting in concert • Polygenic Risk Score is a DNA based risk assessment (screening) tool that weighs a person’s odds of developing common complex diseases by inspect
Slide 8: Polygenic Risk Score vs genetic testing
Polygenic Risk Score For personal use only How do Polygenic Risk Scores differ from genetic testing (e.g. BRCA in breast cancer)? • Genetic testing only captures hereditary forms of disease (e.g. inherited cancer risk) • Polygenic Risk Scores capture sporadic (non-inherited) disease, the most common
Slide 9: Justification of using Polygenic Risk Score for earlier screening
The justification of using Polygenic Risk Score to inform earlier screening is similar across disease types For personal use only Breast cancer Colorectal cancer Coronary heart disease Mavaddat et al. (2015) JNCI Jenkins et al. (2019) Familial Cancer Abraham et al. (2016) Eur Heart J. 7
Slide 10: The unmet need
The unmet need For personal use only • Current genetic testing only captures hereditary forms of disease • Current system is binary - everyone is tested regardless of personal risk status • Currently system is inefficient with a one-size-fits-all policy based on averages • Unable to clearly identify
Slide 11: Intellectual property is a core advantage
Intellectual property is a core advantage For personal use only GTG has a strong patent portfolio covering the breast cancer risk assessment test 5 Patents granted in the US 7 Patent families pending • Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included
Slide 12: Operational overview
Operational overview For personal use only Genetic Technologies Limited Melbourne, Australia • Technical and corporate support • CLIA approved laboratory Phenogen Sciences Inc. Charlotte, North Carolina, USA • Clinical and customer support • Sales and marketing • Liaison for US collaboration 10
Slide 13: Our board
Our board For personal use only Dr. Jerzy “George” Muchnicki Dr. Lindsay Wakefield MBBS MBBS Executive Director & Chief Executive Officer (Interim) Non – Executive Director Mr. Peter Rubinstein Mr Nick Burrows B.Com, FAICD, FCA, FGIA, FTIA, F Fin BSc, BEc, LLB Non – Executive Director Non – Executiv
Slide 14: Our vision
Our vision For personal use only • Identify and manage patients who are at high risk of developing major life threatening diseases • Implement the current protective medical strategies in the best way possible for identified high risk groups via: • targeted screening • lifestyle changes • chemoproph
Slide 15: Product overview
For personal use only Product overview
Slide 16: Product range and status
Product range and status • Our breast and colorectal cancer products are market ready For personal use only • T2D and CV tests are in final stages of development 2Q 2019 Enhanced Breast Cancer* 1Q 2020 Colorectal Cardiovascular Cancer* Test validation 3Q 2020 Type 2 Diabetes Cardiovascular Test vali
Slide 17: Disease coverage
Disease coverage For personal use only • Our product development strategy aims to provide coverage of the most significant causes of morbidity and mortality in the US • It covers up to 70% of causes of mortality Incidence of underlying causes of mortality in the US Breast Cancer Colorectal Cancer Ty
Slide 18: GeneType for Breast Cancer
For personal use only GeneType for Breast Cancer 16
Slide 19: Breast cancer at a glance
Breast cancer at a glance For personal use only • 1 in 8 women will get breast cancer in their lifetime • Every year approximately 270,000 women will be diagnosed with breast cancer • 25% of breast cancers develop before the age of 50 (average age 62) • 85% of women have no family history of breast
Slide 20: Average (asymptomatic) woman at a glance
Average (asymptomatic) woman at a glance For personal use only • Majority of women do NOT have family history of breast cancer • Misconception that lack of FH means lower risk of breast cancer thus they tend be less screen-compliant Percentage of women (40+) with dense breast tissue Up-to-date mammo
Slide 21: GeneType for Breast Cancer
GeneType for Breast Cancer For personal use only • GeneType for Breast Cancer (GeneTypeBC) is a first-to-market, clinically validated genetic risk assessment for non-hereditary (sporadic) breast cancer which represents up to 90% of all breast cancers • It is the world’s first validated genomic test
Slide 22: Targeted screening and prevention
Targeted screening and prevention For personal use only Screening GeneType for More frequent mammograms or MRIs Breast Cancer enables the targeting of limited Medication resources to Selective estrogen receptor modulators (SERMs) or women who are aromatase inhibitors (AIs) most likely to develop bre
Slide 23: Identify at-risk women = Better outcomes
Identify at-risk women = Better outcomes For personal use only Screening Risk reduction • By implementing enhanced surveillance of high- • By qualifying high-risk women for risk reducing risk individuals, you enable clinicians to improve medications, you enable clinicians to reduce breast cancer det
Slide 24: Early diagnosis = Less expensive treatment
Early diagnosis = Less expensive treatment For personal use only Stage I…………………….$ 55,000 First year treatment costs Stage II……………..…….$103,000 for breast cancer Stage III and IV………….$150,000+ USD, study based on US patients, 2003-2010 https://journals.plos.org/plosone/article/figure?id=10.1371/jour
Slide 25: Wider age and population coverage
Wider age and population coverage For personal use only • GeneType for Breast Cancer tests individuals before age of 35 and covers the African American and Hispanic population 23
Slide 26: GeneType for Colorectal Cancer
For personal use only GeneType for Colorectal Cancer 24
Slide 27: Colorectal cancer at a glance
Colorectal cancer at a glance For personal use only • 150,000 people are diagnosed with colorectal • More than 50% of colorectal cancer are first cancer every year in US identified in late stage • 1 in 20 will get colorectal cancer in their lifetime • 69% 5-year survival rate • Screening begins at 4
Slide 28: Distribution of lifetime colorectal cancer risk by polygenic risk and family history
Distribution of lifetime colorectal cancer risk stratified by polygenic risk and family history For personal use only • Risk of acquiring the disease as a high-risk individual is earlier • Family history is potent in identifying risk • Can't look at genomics alone Jenkins MA, Win AK, Dowty JG, et al
Slide 29: World-first polygenic risk test for colorectal cancer
GTG has developed a world-first polygenic risk test for colorectal cancer For personal use only Easy-to-use test solves the compliance problem Risk stratification enables precision screening and personalised prevention Clinically actionable results 5-year, 10-year and lifetime risk Informs screening
Slide 30: Commercialization Strategy
For personal use only Commercialization Strategy
Slide 31: Reaching as many lives as possible through partnerships
We aim to touch as many lives as possible through partnerships (network) For personal use only Partnership Clinics/CIT Partner with genomics market leaders Q1 2020 Launch GeneType product to integrate Genetic Technologies’ line: tests into their testing platforms: • Consumer initiated • White label/
Slide 32: Partnering as an OEM/white label test
Partnering as an OEM/white label test Genetic Technologies is seeking to market its polygenic risk score tests as part of a For personal use only wider offering by established genomic testing market leaders Our partner should : • Be a market leader in CIT or DTC genomics space • Have a large pool of
Slide 33: Consumer Initiated Testing
Consumer Initiated Testing For personal use only More people are taking control of their health CIT Will allow Genetic Technologies to offer Polygenic Risk Score tests directly to consumers • Genetic Technologies is in discussions with a leading provider of CIT services that will Provide outsourced
Slide 34: Existing network of clinics
Existing network of clinics For personal use only • Genetic Technologies plans to leverage existing relationships with its network of clinics • Strong demand from clinicians familiar with the products and the value proposition of Polygenic Risk Testing • Clinics used to offer Genetic Technologies’ p
Slide 35: Validation, Collaboration and Academic Partnerships
For personal use only Validation, Collaboration and Academic Partnerships
Slide 36: TGen: Collaborative Network
Translational Genomics Research Institute (TGen): Collaborative Network For personal use only Background Areas of Disease Focus - Est. 2002 Health Care Partners: - Oncology - Non-profit (501c3) Community hospitals, health care - Neurology - Patient-focused clinical & basic research systems, and onco
Slide 37: Collaboration is a key market advantage
Collaboration is a key market advantage For personal use only The University of Melbourne • Australia’s peak research-intensive institution, ranked 32nd globally Our collaboration with The University of Melbourne was awarded an NHMRC grant • Research investigation to assess the improvement in breast
Slide 38: Research into clinical applications
Research into clinical applications For personal use only GTG has an agreement in place with Memorial Sloan Kettering (MSK) and University of Cambridge • The research is led by Mark E. Robson, MD, Chief of Breast Medicine Service, Memorial Sloan Kettering • MSK is the world’s oldest and largest canc
Slide 39: Other key partnerships
Other key partnerships For personal use only Ohio State University (Columbus, Ohio) • Research collaboration exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations • Led by Amanda Toland, Director of Clinical Genetics and a leader in the field of breast ca
Slide 40: Genetic Technologies' snapshot
Genetic Technologies’ snapshot For personal use only • Current market cap as of 9/01/2020: $27.9M • Dual listed ASX/NASDAQ • App. No. Shares on issue: 4,000,000,000 (ADR @ 600:1) • $US 3M cash as of 31 December 2019 • Company funded out to Q1 2021 based on current business plan 38
Slide 41: An exciting year ahead for Genetic Technologies
An exciting year ahead for Genetic Technologies Upcoming catalysts aim to increase revenues and generate shareholder value For personal use only • GeneType for Breast Cancer and GeneType for Colorectal cancer market ready Q1 2020 • Start US Sales and marketing through existing clinician network • St
Slide 42: Thank you
Thank you For personal use only Dr George Muchnicki Executive Director and Interim CEO george.muchnicki@gtglabs.com www.gtglabs.com 40